Skip to main content
SpringerLink
Log in

Ivabradine in Patients with Stable Coronary Artery Disease: A Rationale for Use in Addition to and Beyond Percutaneous Coronary Intervention

  • Review Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Heart rate is an established prognostic marker for longevity and is an important contributor in the pathophysiology of various cardiovascular diseases, including ischemic heart disease and heart failure. Most ischemic episodes are triggered by an increase in heart rate, which causes an imbalance between myocardial oxygen delivery and consumption. In addition, increased heart rate is a modifiable risk factor for chronic heart failure. Ivabradine, an inhibitor of If ion channels, is an approved second-line anti-ischemic drug for the treatment of angina. Ivabradine has been shown to decrease the risk of hospitalization in patients with chronic heart failure who were previously treated with β-blockers, renin-angiotensin system blockers or mineralocorticoid receptor antagonists. This review describes the rationale for the pathophysiological and clinical use of ivabradine as an anti-ischemic agent in patients with stable coronary disease and highlights its benefits and drawbacks compared with other first- and second-line anti-anginal drugs. The review also highlights the role of ivabradine as a treatment for patients with high-risk coronary artery disease in whom first-line anti-anginal drugs are insufficient or inadequate and percutaneous coronary intervention is contraindicated or revascularization is incomplete or unsuitable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

(adapted from Di Francesco et al. with permission from the publisher. Drugs 2004 [9])

Fig. 2

(adapted from Colin et al., with permission from the publisher. Am J Physiol Heart Circ Physiol 2002 [11])

Fig. 3

(adapted from Monnet et al. with permission from the publisher. J Pharmacol Exp Ther 2001 [13])

Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Benetos A, Rudnichi A, Thomas F, Safar M, Guize L. Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. Hypertension. 1999;33:44–52.

    Article  CAS  PubMed  Google Scholar 

  2. Guth BD, Heusch G, Seitelberger R, Matsuzaki M, Ross J, Jr. Role of heart rate reduction in the treatment of exercise-induced myocardial ischaemia. Eur Heart J. 1987;8(Suppl L):61–68.

  3. Hjalmarson A, Gilpin EA, Kjekshus J, Schieman G, Nicod P, Henning H, et al. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol. 1990;65:547–53.

    Article  CAS  PubMed  Google Scholar 

  4. Indolfi C, Ross J Jr. The role of heart rate in myocardial ischemia and infarction: implications of myocardial perfusion-contraction matching. Prog Cardiovasc Dis. 1993;36:61–74.

    Article  CAS  PubMed  Google Scholar 

  5. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949–3003.

    Article  PubMed  Google Scholar 

  6. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803–69.

    Article  CAS  PubMed  Google Scholar 

  7. Thollon C, Bidouard JP, Cambarrat C, Lesage L, Reure H, Delescluse I, et al. Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257. Eur J Pharmacol. 1997;339:43–51.

    Article  CAS  PubMed  Google Scholar 

  8. Zagotta WN, Olivier NB, Black KD, Young EC, Olson R, Gouaux E. Structural basis for modulation and agonist specificity of HCN pacemaker channels. Nature. 2003;425:200–5.

    Article  CAS  PubMed  Google Scholar 

  9. DiFrancesco D, Camm JA. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004;64:1757–65.

    Article  CAS  PubMed  Google Scholar 

  10. Thollon C, Cambarrat C, Vian J, Prost JF, Peglion JL, Vilaine JP. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol. 1994;112:37–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Colin P, Ghaleh B, Hittinger L, Monnet X, Slama M, Giudicelli JF, et al. Differential effects of heart rate reduction and β-blockade on left ventricular relaxation during exercise. Am J Physiol Heart Circ Physiol. 2002;282:H672–9.

    Article  CAS  PubMed  Google Scholar 

  12. Vilaine JP, Bidouard JP, Lesage L, Reure H, Péglion JL. Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs. J Cardiovasc Pharmacol. 2003;42:688–96.

    Article  CAS  PubMed  Google Scholar 

  13. Monnet X, Ghaleh B, Colin P, de Curzon OP, Giudicelli JF, Berdeaux A. Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning. J Pharmacol Exp Ther. 2001;299:1133–9.

    CAS  PubMed  Google Scholar 

  14. Simon L, Ghaleh B, Puybasset L, Giudicelli JF, Berdeaux A. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther. 1995;275:659–66.

    CAS  PubMed  Google Scholar 

  15. Colin P, Ghaleh B, Monnet X, Su J, Hittinger L, Giudicelli JF, et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol. 2003;284:H676–82.

    Article  CAS  PubMed  Google Scholar 

  16. Du XJ, Feng X, Gao XM, Tan TP, Kiriazis H, Dart AM. I(f) channel inhibitor ivabradine lowers heart rate in mice with enhanced sympathoadrenergic activities. Br J Pharmacol. 2004;142:107–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol. 2008;153:1589–601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Lucats L, Ghaleh B, Monnet X, Colin P, Bize A, Berdeaux A. Conversion of post-systolic wall thickening into ejectional thickening by selective heart rate reduction during myocardial stunning. Eur Heart J. 2007;28:872–9.

    Article  PubMed  Google Scholar 

  19. Rose J, Schulz R, Martin C, Heusch G. Post-ejection wall thickening as a marker of successful short term hibernation. Cardiovasc Res. 1993;27:1306–11.

    Article  CAS  PubMed  Google Scholar 

  20. Lucats L, Ghaleh B, Colin P, Monnet X, Bize A, Berdeaux A. Heart rate reduction by inhibition of If or by β-blockade has different effects on postsystolic wall thickening. Br J Pharmacol. 2007;150:335–41.

    Article  CAS  PubMed  Google Scholar 

  21. Bucchi A, Baruscotti M, DiFrancesco D. Current-dependent block of rabbit sino-atrial node I(f) channels by ivabradine. J Gen Physiol. 2002;120:1–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Scicchitano P, Carbonara S, Ricci G, Mandurino C, Locorotondo M, Bulzis G, et al. HCN channels and heart rate. Molecules. 2012;17:4225–35.

    Article  CAS  PubMed  Google Scholar 

  23. Fox K, Komajda M, Ford I, Robertson M, Böhm M, Borer JS, et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Eur Heart J. 2013;34:2263–70.

    Article  CAS  PubMed  Google Scholar 

  24. Baumgart D, Ehring T, Heusch G. A proischaemic action of nisoldipine: relationship to a decrease in perfusion pressure and comparison to dipyridamole. Cardiovasc Res. 1993;27:1254–9.

    Article  CAS  PubMed  Google Scholar 

  25. Heusch G, Yoshimoto N. Effects of heart rate and perfusion pressure on segmental coronary resistances and collateral perfusion. Pflügers Archiv. 1983;397:284–9.

    Article  CAS  PubMed  Google Scholar 

  26. Heusch G, Yoshimoto N, Muller-Ruchholtz ER. Effects of heart rate on hemodynamic severity of coronary artery stenosis in the dog. Basic Res Cardiol. 1982;77:562–73.

    Article  CAS  PubMed  Google Scholar 

  27. Seitelberger R, Guth BD, Heusch G, Lee JD, Katayama K, Ross J Jr. Intracoronary α2-adrenergic receptor blockade attenuates ischemia in conscious dogs during exercise. Circ Res. 1988;62:436–42.

    Article  CAS  PubMed  Google Scholar 

  28. Baumgart D, Haude M, Görge G, Liu F, Ge J, Grosse-Eggebrecht C, et al. Augmented α-adrenergic constriction of atherosclerotic human coronary arteries. Circulation. 1999;99:2090–7.

    Article  CAS  PubMed  Google Scholar 

  29. Heusch G, Baumgart D, Camici P, Chilian W, Gregorini L, Hess O, et al. α-adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation. 2000;101:689–94.

    Article  CAS  PubMed  Google Scholar 

  30. Guth BD, Heusch G, Seitelberger R, Ross J Jr. Mechanism of beneficial effect of beta-adrenergic blockade on exercise-induced myocardial ischemia in conscious dogs. Circ Res. 1987;60:738–46.

    Article  CAS  PubMed  Google Scholar 

  31. Buck JD, Hardman HF, Warltier DC, Gross GJ. Changes in ischemic blood flow distribution and dynamic severity of a coronary stenosis induced by beta blockade in the canine heart. Circulation. 1981;64:708–15.

    Article  CAS  PubMed  Google Scholar 

  32. Matsuzaki M, Patritti J, Tajimi T, Miller M, Kemper WS, Ross J Jr. Effects of beta-blockade on regional myocardial flow and function during exercise. Am J Physiol. 1984;247:H52–60.

    CAS  PubMed  Google Scholar 

  33. Tagliamonte E, Cirillo T, Rigo F, Astarita C, Coppola A, Romano C, et al. Ivabradine and bisoprolol on doppler-derived coronary low velocity reserve in patients with stable coronary artery disease: beyond the heart rate. Adv Ther. 2015;32:757–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Gloekler S, Traupe T, Stoller M, Schild D, Steck H, Khattab A, et al. The effect of heart rate reduction by ivabradine on collateral function in patients with chronic stable coronary artery disease. Heart. 2014;100:160–6.

    Article  PubMed  Google Scholar 

  35. Zuanetti G, Mantini L, Hernandez-Bernal F, Barlera S, di Gregorio D, Latini R, et al. Relevance of heart rate as a prognostic factor in patients with acute myocardial infarction: insights from the GISSI-2 study. Eur Heart J. 1998;19(Suppl F):F19–26.

  36. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807–16.

    Article  CAS  PubMed  Google Scholar 

  37. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372:817–21.

    Article  PubMed  Google Scholar 

  38. Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371:1091–9.

    Article  PubMed  Google Scholar 

  39. Bangalore S, Bhatt DL, Steg PG, Weber MA, Boden WE, Hamm CW, et al. β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes. 2014;7:872–81.

    Article  PubMed  Google Scholar 

  40. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, et al. β-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308:1340–9.

    Article  CAS  PubMed  Google Scholar 

  41. Bao B, Ozasa N, Morimoto T, Furukawa Y, Nakagawa Y, Kadota K, et al. β-blocker therapy and cardiovascular outcomes in patients who have undergone percutaneous coronary intervention after ST-elevation myocardial infarction. Cardiovasc Interv Ther. 2013;28:139–47.

    Article  CAS  PubMed  Google Scholar 

  42. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–16.

    Article  CAS  PubMed  Google Scholar 

  43. Danchin N, Laurent S. Coronary artery disease. Are β-blockers truly helpful in patients with CAD? Nat Rev Cardiol. 2013;10:11–2.

    Article  PubMed  Google Scholar 

  44. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. 1986;2:57–66.

  45. Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study. Eur Heart J. 2015;36:3291–6.

    PubMed  Google Scholar 

  46. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26:2529–36.

    Article  CAS  PubMed  Google Scholar 

  47. Amosova E, Andrejev E, Zaderey I, Rudenko U, Ceconi C, Ferrari R. Efficacy of ivabradine in combination with Beta-blocker versus uptitration of Beta-blocker in patients with stable angina. Cardiovasc Drugs Ther. 2011;25:531–7.

    Article  CAS  PubMed  Google Scholar 

  48. Koester R, Kaehler J, Ebelt H, Soeffker G, Werdan K, Meinertz T. Ivabradine in combination with beta-blocker therapy for the treatment of stable angina pectoris in every day clinical practice. Clin Res Cardiol. 2010;99:665–72.

    Article  CAS  PubMed  Google Scholar 

  49. Koester R, Kaehler J, Meinertz T. Ivabradine for the treatment of stable angina pectoris in octogenarians. Clin Res Cardiol. 2011;100:121–8.

    Article  CAS  PubMed  Google Scholar 

  50. Werdan K, Ebelt H, Nuding S, Höpfner F, Hack G, Müller-Werdan U. Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol. 2012;101:365–73.

    Article  CAS  PubMed  Google Scholar 

  51. Werdan K, Ebelt H, Nuding S, Höpfner F, Stöckl G, Müller-Werdan U. Ivabradine in combination with beta-blockers in patients with chronic stable angina after percutaneous coronary intervention. Adv Ther. 2015;32:120–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Martin RI, Pogoryelova O, Koref MS, Bourke JP, Teare MD, Keavney BD. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart. 2014;100:1506–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875–85.

    Article  CAS  PubMed  Google Scholar 

  54. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367:991–1001.

    Article  PubMed  Google Scholar 

  55. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503–15.

    Article  CAS  PubMed  Google Scholar 

  56. Pursnani S, Korley F, Gopaul R, Kanade P, Chandra N, Shaw RE, et al. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials. Circ Cardiovasc Interv. 2012;5:476–90.

    Article  PubMed  Google Scholar 

  57. Stergiopoulos K, Brown DL. Initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease: meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172:312–9.

    Article  PubMed  Google Scholar 

  58. Thomas S, Gokhale R, Boden WE, Devereaux PJ. A meta-analysis of randomized controlled trials comparing percutaneous coronary intervention with medical therapy in stable angina pectoris. Can J Cardiol. 2013;29:472–82.

    Article  PubMed  Google Scholar 

  59. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart. 2006;92(Suppl 4):iv6–iv14.

  60. Hayashida W, van Eyll C, Rousseau MF, Pouleur H. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc Drugs Ther. 1994;8:741–7.

    Article  CAS  PubMed  Google Scholar 

  61. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375–82.

    Article  CAS  PubMed  Google Scholar 

  62. Schuler J, Maier B, Behrens S, Thimme W. Present treatment of acute myocardial infarction in patients over 75 years–data from the Berlin Myocardial Infarction Registry (BHIR). Clin Res Cardiol. 2006;95:360–7.

    Article  PubMed  Google Scholar 

  63. Müller-Werdan U, Stöckl G, Ebelt H, Nuding S, Höpfner F, Werdan K. Ivabradine in combination with beta-blocker reduces symptoms and improves quality of life in elderly patients with stable angina pectoris: age-related results from the ADDITIONS study. Exp Gerontol. 2014;59:34–41.

    Article  PubMed  Google Scholar 

  64. Fragasso G, Piatti Md PM, Monti L, Palloshi A, Setola E, Puccetti P, et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J. 2003;146:E18.

    Article  CAS  PubMed  Google Scholar 

  65. Xu X, Zhang W, Zhou Y, Zhao Y, Liu Y, Shi D, et al. Effect of trimetazidine on recurrent angina pectoris and left ventricular structure in elderly multivessel coronary heart disease patients with diabetes mellitus after drug-eluting stent implantation: a single-centre, prospective, randomized, double-blind study at 2-year follow-up. Clin Drug Investig. 2014;34:251–8.

    Article  CAS  PubMed  Google Scholar 

  66. Field ME, Solomon SD, Lewis EF, Kramer DB, Baughman KL, Stevenson LW, et al. Right ventricular dysfunction and adverse outcome in patients with advanced heart failure. J Card Fail. 2006;12:616–20.

    Article  PubMed  Google Scholar 

  67. Meyer P, Filippatos GS, Ahmed MI, Iskandrian AE, Bittner V, Perry GJ, et al. Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure. Circulation. 2010;121:252–8.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Polak JF, Holman BL, Wynne J, Colucci WS. Right ventricular ejection fraction: an indicator of increased mortality in patients with congestive heart failure associated with coronary artery disease. J Am Coll Cardiol. 1983;2:217–24.

    Article  CAS  PubMed  Google Scholar 

  69. Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001;37:183–8.

    Article  CAS  PubMed  Google Scholar 

  70. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215–25.

    Article  CAS  PubMed  Google Scholar 

  71. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349–55.

    Article  CAS  PubMed  Google Scholar 

  72. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194–9.

    Article  PubMed  Google Scholar 

  73. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90:1765–73.

    Article  Google Scholar 

  74. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13.

    Article  Google Scholar 

  75. Brocco S, Zamboni M, Fantin F, Marchesan M, Schievano E, Zambon F, et al. Quality of care in congestive heart failure in the elderly: epidemiological evidence of a gap between guidelines and clinical practice. Aging Clin Exp Res. 2010;22:243–8.

    Article  PubMed  Google Scholar 

  76. Peters-Klimm F, Müller-Tasch T, Schellberg D, Remppis A, Barth A, Holzapfel N, et al. Guideline adherence for pharmacotherapy of chronic systolic heart failure in general practice: a closer look on evidence-based therapy. Clin Res Cardiol. 2008;97:244–52.

    Article  CAS  PubMed  Google Scholar 

  77. Shah SM, Carey IM, DeWilde S, Richards N, Cook DG. Trends and inequities in beta-blocker prescribing for heart failure. Br J Gen Pract. 2008;58:862–9.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–33.

    Article  Google Scholar 

  79. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol. 2007;100:1254–62.

    Article  CAS  PubMed  Google Scholar 

  80. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–90.

    Article  CAS  PubMed  Google Scholar 

  81. Messerli FH, Bell DS, Fonseca V, Katholi RE, McGill JB, Phillips RA, et al. Body weight changes with β-blocker use: results from GEMINI. Am J Med. 2007;120:610–5.

    Article  CAS  PubMed  Google Scholar 

  82. Jonsson G, Abdelnoor M, Müller C, Kjeldsen SE, Os I, Westheim A. A comparison of the two β-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical end points after myocardial infarction. a single-centre, randomized study of 232 patients. Cardiology. 2005;103:148–155.

  83. Tölg R, Witt M, Schwarz B, Kurz T, Kurowski V, Hartmann F, et al. Comparison of carvedilol and metoprolol in patients with acute myocardial infarction undergoing primary coronary intervention–the PASSAT Study. Clin Res Cardiol. 2006;95:31–41.

    Article  PubMed  Google Scholar 

  84. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011;58:2432–46.

    Article  PubMed  Google Scholar 

  85. Steg P, Lopez-de-Sa E, Schiele F, Hamon M, Meinertz T, Goicolea J, et al. Safety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a randomized, placebo-controlled, double-blind, pilot study. Eur Heart J Acute Cardiovasc Care. 2013;2:270–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Fasullo S, Cannizzaro S, Maringhini G, Ganci F, Giambanco F, Vitale G, et al. Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings. J Card Fail. 2009;15:856–63.

    Article  CAS  PubMed  Google Scholar 

  87. Patel Y, Depta JP, Novak E, Yeung M, Lavine K, Banerjee S, et al. Long-term outcomes with use of intravascular ultrasound for the treatment of coronary bifurcation lesions. Am J Cardiol. 2012;109:960–5.

    Article  PubMed  Google Scholar 

  88. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126–30.

    Article  CAS  PubMed  Google Scholar 

  89. Latib A, Colombo A. Bifurcation disease: what do we know, what should we do? JACC Cardiovasc Interv. 2008;1:218–26.

    Article  PubMed  Google Scholar 

  90. Iakovou I, Ge L, Colombo A. Contemporary stent treatment of coronary bifurcations. J Am Coll Cardiol. 2005;46:1446–55.

    Article  PubMed  Google Scholar 

  91. Ferenc M, Gick M, Kienzle RP, Bestehorn HP, Werner KD, Comberg T, et al. Long-term outcome of percutaneous catheter intervention for de novo coronary bifurcation lesions with drug-eluting stents or bare-metal stents. Am Heart J. 2010;159:454–61.

    Article  CAS  PubMed  Google Scholar 

  92. Maeng M, Holm NR, Erglis A, Kumsars I, Niemela M, Kervinen K, et al. Long-term results after simple versus complex stenting of coronary artery bifurcation lesions: Nordic Bifurcation Study 5-year follow-up results. J Am Coll Cardiol. 2013;62:30–4.

    Article  PubMed  Google Scholar 

  93. Behan MW, Holm NR, Curzen NP, Erglis A, Stables RH, de Belder AJ, et al. Simple or complex stenting for bifurcation coronary lesions: a patient-level pooled-analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study. Circ Cardiovasc Interv. 2011;4:57–64.

    Article  PubMed  Google Scholar 

  94. Hildick-Smith D, de Belder AJ, Cooter N, Curzen NP, Clayton TC, Oldroyd KG, et al. Randomized trial of simple versus complex drug-eluting stenting for bifurcation lesions: the British Bifurcation Coronary Study: old, new, and evolving strategies. Circulation. 2010;121:1235–43.

    Article  CAS  PubMed  Google Scholar 

  95. Song YB, Hahn JY, Song PS, Yang JH, Choi JH, Choi SH, et al. Randomized comparison of conservative versus aggressive strategy for provisional side branch intervention in coronary bifurcation lesions: results from the SMART-STRATEGY (Smart Angioplasty Research Team-Optimal Strategy for Side Branch Intervention in Coronary Bifurcation Lesions) randomized trial. JACC Cardiovasc Interv. 2012;5:1133–40.

    Article  PubMed  Google Scholar 

  96. Ahn JM, Lee JY, Kang SJ, Kim YH, Song HG, Oh JH, et al. Functional assessment of jailed side branches in coronary bifurcation lesions using fractional flow reserve. JACC Cardiovasc Interv. 2012;5:155–61.

    Article  PubMed  Google Scholar 

  97. Basavarajaiah S, Naganuma T, Latib A, Hasegawa T, Sharp A, Rezq A, et al. Extended follow-up following “full-metal jacket” percutaneous coronary interventions with drug-eluting stents. Catheter Cardiovasc Interv. 2014;84:1042–50.

    Article  PubMed  Google Scholar 

  98. Calé R, Teles RC, Almeida M, Rosário I, Sousa PJ, Brito J, et al. Percutaneous coronary intervention using a full metal jacket with drug-eluting stents: major adverse cardiac events at one year. Arq Bras Cardiol. 2013;101:117–26.

    PubMed  PubMed Central  Google Scholar 

  99. Di Mario C, Werner GS, Sianos G, Galassi AR, Buttner J, Dudek D, et al. European perspective in the recanalisation of Chronic Total Occlusions (CTO): consensus document from the EuroCTO Club. EuroIntervention. 2007;3:30–43.

    Article  PubMed  Google Scholar 

  100. Godino C, Maccagni D, Pavon AG, Viani G, Cappelletti A, Margonato A, et al. Estimating incidence of organ cancer related to PCI radiation exposure in patients treated for acute and chronic total occlusions. J Invasive Cardiol. 2013;25:441–5.

    PubMed  Google Scholar 

  101. Lin YS, Fang HY, Hussein H, Fang CY, Chen YL, Hsueh SK, et al. Predictors of contrast-induced nephropathy in chronic total occlusion percutaneous coronary intervention. EuroIntervention. 2014;9:1173–80.

    Article  PubMed  Google Scholar 

  102. Michael TT, Karmpaliotis D, Brilakis ES, Alomar M, Abdullah SM, Kirkland BL, et al. Temporal trends of fluoroscopy time and contrast utilization in coronary chronic total occlusion revascularization: insights from a multicenter United States registry. Catheter Cardiovasc Interv. 2015;85:393–9.

    Article  PubMed  Google Scholar 

  103. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–619.

    Article  PubMed  Google Scholar 

  104. Godino C, Bassanelli G, Economou FI, Takagi K, Ancona M, Galaverna S, et al. Predictors of cardiac death in patients with coronary chronic total occlusion not revascularized by PCI. Int J Cardiol. 2013;168:1402–9.

    Article  PubMed  Google Scholar 

  105. Mehran R, Claessen BE, Godino C, Dangas GD, Obunai K, Kanwal S, et al. Long-term outcome of percutaneous coronary intervention for chronic total occlusions. JACC Cardiovasc Interv. 2011;4:952–61.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Medical writing assistance (English editing and formatting) for submission was provided by Cécile Duchesnes, PhD, and medical writing assistance (English editing) post-submission was provided by Nishad Parkar, PhD, both of Springer Healthcare Communications. This assistance was supported by Servier.

Authors’ contributions

Dr. Cosmo Godino contributed to the design and concept of the manuscript and reviewed all the literature reported. Prof. Alberto Margonato and Prof. Antonio Colombo revised the text and contributed to the major concept regarding the use of ivabradine in the context of PCI. All the authors approved the manuscript before submission.

Author information

Authors and Affiliations

  1. Cardio-Thoracic-Vascular Department, San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy

    Cosmo Godino, Antonio Colombo & Alberto Margonato

  2. EMO-GVM Centro Cuore Columbus, Milan, Italy

    Antonio Colombo

Authors
  1. Cosmo Godino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonio Colombo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alberto Margonato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cosmo Godino.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Godino, C., Colombo, A. & Margonato, A. Ivabradine in Patients with Stable Coronary Artery Disease: A Rationale for Use in Addition to and Beyond Percutaneous Coronary Intervention. Clin Drug Investig 37, 105–120 (2017). https://doi.org/10.1007/s40261-016-0472-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-016-0472-1

Keywords

Search

Navigation